Physician profile
Claudia Sickinger
NPI 1053534115
$3,333.16
in general payments reported to CMS, 2019-2025
24 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Psychosomatic Medicine provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $262 · 2021: $327 · 2022: $202 · 2023: $455 · 2024: $306 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $389.17 | 2019 | |
| Abbvie INC. | $387.83 | 2021-2024 | Vraylar, Qulipta |
| Lundbeck LLC | $319.97 | 2019-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $260.17 | 2019-2025 | Spravato |
| Neuronetics, INC. | $254.14 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $235.45 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $215.91 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $168.12 | 2019-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $157.06 | 2019-2021 | |
| Corium, LLC | $150.82 | 2023-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $145.63 | 2022-2025 | Cobenfy |
| Bausch Health US, LLC | $131.31 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $112.77 | 2025 | Rejoyn |
| Vanda Pharmaceuticals INC. | $74.55 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $72.87 | 2019-2023 | Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $54.83 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.01 | 2023-2024 | Caplyta |
| Avanir Pharmaceuticals, INC. | $40.36 | 2020-2021 | |
| Axsome Therapeutics, INC. | $26.51 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $20.24 | 2022 | |
| Glaxosmithkline, LLC. | $20.03 | 2022 | |
| Alfasigma USA, INC. | $16.67 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.64 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $16.10 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Sickinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.